MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Incyte Corp

Fermé

SecteurSoins de santé

68.7 1.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

66.8

Max

70.34

Chiffres clés

By Trading Economics

Revenu

-43M

158M

Ventes

-126M

1.1B

P/E

Moyenne du Secteur

336.3

50.291

BPA

1.16

Marge bénéficiaire

15.025

Employés

2,617

EBITDA

-80M

257M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+12.06% upside

Dividendes

By Dow Jones

Prochains Résultats

29 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3.1B

13B

Ouverture précédente

67.54

Clôture précédente

68.7

Sentiment de l'Actualité

By Acuity

7%

93%

2 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2025, 23:09 UTC

Résultats

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 juil. 2025, 19:16 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 juil. 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 juil. 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 juil. 2025, 22:23 UTC

Acquisitions, Fusions, Rachats

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 juil. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

James Hardie Completes Acquisition of AZEK

1 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 juil. 2025, 20:24 UTC

Résultats

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 juil. 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 juil. 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 juil. 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 juil. 2025, 19:01 UTC

Acquisitions, Fusions, Rachats

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 juil. 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 juil. 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 juil. 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 juil. 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 juil. 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 juil. 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 juil. 2025, 17:01 UTC

Acquisitions, Fusions, Rachats

Danone Completed Acquisition of Majority Stake in Kate Farms

1 juil. 2025, 16:55 UTC

Résultats

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 juil. 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 juil. 2025, 16:25 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 juil. 2025, 15:48 UTC

Market Talk
Acquisitions, Fusions, Rachats

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 juil. 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 juil. 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 juil. 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

12.06% hausse

Prévisions sur 12 Mois

Moyen 76.31 USD  12.06%

Haut 107 USD

Bas 52 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

7

Achat

9

Maintien

1

Vente

Score Technique

By Trading Central

59.52 / 62.66Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

2 / 380Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation